The Latest Articles from Streetwise Reports


News Update

Biopharma Receives PDUFA Goal Date for Nonopioid Pain Drug

News Update
  ()
The FDA deemed the firm's submission for analgesic approval complete. read more >

Top Pick Status Given to Small-Cap with Pain Drug Candidate

Research Report
  ()
The primary reason for the rating—upcoming trial results—is discussed in an Echelon Wealth Partners report. read more >

Biotech Demonstrates Superiority of Polyp-Detecting Product

Research Report
  ()
The study results and their meaning are reviewed in an H.C. Wainwright & Co. report. read more >
News Update

Canadian Firm to Sell THC Cannabis Oil-Filled Capsules

News Update
  ()
The product will be launched under its brand for the recreational market. read more >
News Update

Biotech Incorporates Urologists' Feedback Into Device Design

News Update
  ()
This step moves the product further down the development track. read more >

Seattle Genetics Shares Head Higher After Positive Earnings and ADCETRIS Sales Expansion

  ()
Seattle Genetics announced a 28.3% increase in net sales for its second quarter 2019 powered by ADCETRIS sales along with a promising pipeline. read more >
News Update

Logistics Firm Expands Into Another Cannabis Industry Segment

News Update
  ()
Its newly entered agreement offers potential for future growth in Canada. read more >

Biopharma's Brain Cancer Therapeutic Compelling, Its Stock Undervalued

Research Report
  ()
A description of the asset and its potential are provided in a Dawson James report. read more >

Galapagos Agrees to $3.95 Billion, 10-Year Licensing Deal Plus $1.1 Billion Investment from Gilead

  ()
Galapagos announced that Gilead Sciences has agreed to pay $3.95 billion for a 10-year partnership and licensing deal and will invest an additional $1.1 billion in newly issued shares of the company. read more >

Technical Analyst: Medical Device Stock Looking Set to Reverse

Contributed Opinion
  ()
Technical analyst Clive Maund charts the stock of this company that has developed a device that uses a special light that visualizes cancer during minimally invasive surgery. read more >

Illumina Shares Fall Sharply on Lower Revenue Guidance

  ()
Illumina Inc. shares traded down more than 15% as the company reported lower preliminary Q2/19 revenues and updated its annual revenue guidance. read more >

CVS Declares Quarterly Dividend and Gets a Boost from Relaxed Rebate Policy

  ()
CVS Healthcare announced a $0.50/share quarterly dividend and got an added boost as news spreads regarding easing of federal restrictions on pharmacy rebate plans. read more >
News Update

Physician Testing of EMR-Integrated, Medical Cannabis Evaluation Tool Completed

News Update
  ()
The two firms involved plan to have the offering fully rolled out by Q3/19. read more >

Biopharma Starts 'Key Catalyst Period,' H2/19, with Clinical Trial in New Indication

Research Report
  ()
A study description and expected data readouts this year are provided in a ROTH Capital Partners report. read more >

Coverage Initiated on U.S. Biotech with a 'Potential Best-of-Breed Oncolytic Virus'

Research Report
  ()
The investment thesis on this immunotherapies developer is made in an H.C. Wainwright & Co. report. read more >

Sangamo and Pfizer Report Positive Results for Hemophilia A Study

  ()
Sangamo Therapeutics and partner Pfizer reported positive results for phase 1/2 Alta study for hemophilia A at the International Society on Thrombosis and Hemostasis Congress in Melbourne, Australia. read more >

Coverage Initiated on Biopharma With 'Low Risk/High Margin Assets'

Research Report
  ()
The case is made in a ROTH Capital Partners report for investing in this U.S.-based pharma having multiple shots on goal. read more >

Health Technology Company Recuperating Well

Contributed Opinion
  ()
Technical analyst Clive Maund charts a medical technology firm and explains why he believes it is an interesting speculative play. read more >

Amarin Shares Up Sharply on Increased Revenues and Vascepa's Progress

  ()
Amarin shares are spiking up today by more than 12% on greater than five times 50-day average volume after the company updated its annual revenue forecast and plans for Vascepa. read more >

Bioasis Engages With the FDA: Here's What It Means

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research examines the implications of correspondence with the regulatory agency as the company advances its lead candidate addressing brain cancer. read more >

Biopharma Buys 'Insurance Policy Ahead of First Commercial Launch'

Research Report
  ()
The terms of the financial transaction and the potential reasons for it are discussed in a BTIG report. read more >

Coverage Initiated on Developer of Neurodegenerative Disease Therapeutics

Research Report
  ()
An H.C. Wainwright & Co. report presented the investment bank's reasons for its bullish view on this California-based biotech. read more >
News Update

Biotech's Data Well Received at Neurodegenerative Diseases Symposium

News Update
  ()
The company shared findings from its lead clinical program, in Alzheimer's disease. read more >
News Update

Biopharma Responds to FDA Inquiry Concerning Non-Opioid Pain Reliever

News Update
  ()
The firm believes adequate therapeutic safety and efficacy data exist to support regulatory approval. read more >

Dova Pharmaceuticals Shares Increase 35% Overnight with FDA Approval

  ()
The pharmaceutical stock enjoyed a large boost, thanks largely to FDA approval of its supplemental new drug application for DOPTELET for treatment of chronic immune thrombocytopenia. read more >
Showing Results: 1 to 25 of 128 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"DRRX's capital raise takes care of financing overhang on the stock." ❭
– Francois Brisebois, Laidlaw & Company